Patents by Inventor Daniel J. Canney

Daniel J. Canney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 5-hydroxytryptamine receptor 7 activity modulators and their method of use
    Patent number: 11897870
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Grant
    Filed: April 28, 2020
    Date of Patent: February 13, 2024
    Assignee: Temple University-Of The Commonwealth System Higher Education
    Inventors: Daniel J. Canney, Benjamin E. Blass, Rong Gao, Magid Abou-Gharbia
  • Modulators of the sigma-2 receptor and their method of use
    Patent number: 11820774
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of sigma-2 receptor activity.
    Type: Grant
    Filed: January 21, 2021
    Date of Patent: November 21, 2023
    Assignee: Temple University—Of The Commonwealth System of Higher Education
    Inventors: Benjamin E. Blass, Daniel J. Canney, Kevin M. Blattner
  • 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents
    Patent number: 11807642
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Grant
    Filed: December 3, 2021
    Date of Patent: November 7, 2023
    Assignee: Temple University—Of The Commonwealth System of Higher Education
    Inventors: Benjamin E. Blass, Daniel J. Canney, Kevin M. Blattner
  • NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE
    Publication number: 20230112888
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Application
    Filed: March 31, 2022
    Publication date: April 13, 2023
    Inventors: Daniel J. Canney, Benjamin E. Blass, Kevin M. Blattner, Douglas A. Pippin
  • NOVEL FUNCTIONALIZED LACTONES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE
    Publication number: 20230025932
    Abstract: Described herein are new, selective modulators of the 5-HT7receptor. These selective compounds can be useful for the treatment of CNS and non-CNS indications.
    Type: Application
    Filed: November 12, 2020
    Publication date: January 26, 2023
    Inventors: Daniel J. Canney, Benjamin Blass Blass, Kevin M. Blattner, Douglas A. Pippin
  • NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE
    Publication number: 20230002383
    Abstract: Described herein are new, selective modulators of the 5-HT7 receptor. These selective compounds can be useful for the treatment of CNS and non-CNS indications. Compounds described herein can be selective in targeting 5-HT7 receptors as compared to other receptors and/or by selective targeting 5-HT7 receptors expressed in certain tissues or organs, thereby effective selectivity through a particular partitioning profile of the 5-HT7 modulator.
    Type: Application
    Filed: November 12, 2020
    Publication date: January 5, 2023
    Inventors: Daniel J. Canney, Benjamin E. Blass, Kevin M. Blattner, Douglas A. Pippin
  • 5-HYDROXYTRYPTAMINE RECEPTOR 7 MODULATORS AND THEIR USE AS THERAPEUTIC AGENTS
    Publication number: 20220348581
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Application
    Filed: December 3, 2021
    Publication date: November 3, 2022
    Inventors: Benjamin E. Blass, Daniel J. Canney, Kevin M. Blattner
  • NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE
    Publication number: 20220306596
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Application
    Filed: November 2, 2021
    Publication date: September 29, 2022
    Inventors: Daniel J. Canney, Benjamin E. Blass, Rong Gao, Magid Abou-Gharbia
  • NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE
    Publication number: 20220306629
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactam derivatives of formula (I) having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Application
    Filed: May 10, 2019
    Publication date: September 29, 2022
    Inventors: Daniel J. Canney, Benjamin E. Blass, Kevin M. Blattner, Douglas A. Pippin
  • SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE
    Publication number: 20220133713
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of sigma-2 receptor activity.
    Type: Application
    Filed: June 14, 2021
    Publication date: May 5, 2022
    Inventors: Daniel J. Canney, Benjamin E. Blass, Rong Gao, Kevin Blattner
  • Modulators of the 5-hydroxytryptamine receptor 7 and their method of use
    Patent number: 11319327
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Grant
    Filed: September 9, 2020
    Date of Patent: May 3, 2022
    Assignees: Temple University—Of The Commonwealth System of Higher Education, Praeventix, LLC
    Inventors: Daniel J. Canney, Benjamin E. Blass, Kevin M. Blattner, Douglas A. Pippin
  • 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents
    Patent number: 11220505
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: January 11, 2022
    Assignee: Temple University-Of the Commonwealth System of Higher Education
    Inventors: Benjamin E. Blass, Daniel J. Canney, Kevin M. Blattner
  • 5-hydroxytryptamine receptor 7 activity modulators and their method of use
    Patent number: 11192871
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: December 7, 2021
    Assignee: Temple University-Of The Commonwealth System of Higher Education
    Inventors: Daniel J. Canney, Benjamin E. Blass, Rong Gao, Magid Abou-Gharbia
  • NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE
    Publication number: 20210363145
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of sigma-2 receptor activity.
    Type: Application
    Filed: January 21, 2021
    Publication date: November 25, 2021
    Inventors: Benjamin E. Blass, Daniel J. Canney, Kevin M. Blattner
  • NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE
    Publication number: 20210238189
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Application
    Filed: September 9, 2020
    Publication date: August 5, 2021
    Inventors: Daniel J. Canney, Benjamin E. Blass, Kevin M. Blattner, Douglas A. Pippin
  • Modulators of the sigma-2 receptor and their method of use
    Patent number: 10961249
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of sigma-2 receptor activity.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: March 30, 2021
    Assignee: TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Benjamin E. Blass, Daniel J. Canney, Kevin M. Blattner
  • Modulators of the 5-hydroxytryptamine receptor 7 and their method of use
    Patent number: 10858368
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: December 8, 2020
    Assignees: TEMPLE UNIVERSITY—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, PRAEVENTIX, LLC
    Inventors: Daniel J. Canney, Benjamin E. Blass, Kevin M. Blattner, Douglas A. Pippin
  • 5-HYDROXYTRYPTAMINE RECEPTOR 7 MODULATORS AND THEIR USE AS THERAPEUTIC AGENTS
    Publication number: 20200331915
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Application
    Filed: March 15, 2018
    Publication date: October 22, 2020
    Inventors: Benjamin E. Blass, Daniel J. Canney, Kevin M. Blattner
  • NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE
    Publication number: 20200317648
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Application
    Filed: April 28, 2020
    Publication date: October 8, 2020
    Inventors: Daniel J. Canney, Benjamin E. Blass, Rong Gao, Magid Abou-Gharbia
  • NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE
    Publication number: 20200223810
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Application
    Filed: December 12, 2019
    Publication date: July 16, 2020
    Inventors: Daniel J. Canney, Benjamin E. Blass, Rong Gao, Magid Abou-Gharbia